View ValuationZhejiang NHU 将来の成長Future 基準チェック /26Zhejiang NHU利益と収益がそれぞれ年間11.8%と7.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に20.1% 10%なると予測されています。主要情報11.8%収益成長率9.96%EPS成長率Chemicals 収益成長29.3%収益成長率7.9%将来の株主資本利益率20.15%アナリストカバレッジGood最終更新日24 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Zhejiang NHU Company Ltd. to Report First Half, 2026 Results on Aug 20, 2026Zhejiang NHU Company Ltd. announced that they will report first half, 2026 results on Aug 20, 2026お知らせ • Jun 25Zhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for CNY 600 million worth of its shares.Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 45.5 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan and shares not used within 3 years after the completion of the repurchase will be cancelled. The program will be funded using the company's own funds. The program is valid for 12 months from board approval date.Declared Dividend • May 23Dividend of CN¥0.80 announcedShareholders will receive a dividend of CN¥0.80. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 28% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 16Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang Chinaお知らせ • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2026 Results on Apr 29, 2026Zhejiang NHU Company Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2025 Results on Apr 16, 2026Zhejiang NHU Company Ltd. announced that they will report fiscal year 2025 results on Apr 16, 2026お知らせ • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2025 Results on Oct 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Sep 16Zhejiang Nhu Company Ltd. Approves Interim Dividend for 2025Zhejiang NHU Company Ltd. held its 2nd Extraordinary General Meeting of 2025 on 12 September 2025, approved interim Cash dividend/10 shares (tax included): CNY2.00000000 for 2025.お知らせ • Aug 29Zhejiang Nhu Company Ltd. Proposes Interim Cash Dividend for 2025Zhejiang NHU Company Ltd. proposed 2025 interim dividend at its EGM to be held on 12 September 2025, a Cash dividend (tax included) of CNY 2.00000000 per ten shares.お知らせ • Jul 02Zhejiang NHU Company Ltd. to Report First Half, 2025 Results on Aug 28, 2025Zhejiang NHU Company Ltd. announced that they will report first half, 2025 results on Aug 28, 2025お知らせ • Apr 16+ 1 more updateZhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for $600 million worth of its shares.Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 32 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan. The program will be funded using the company's own funds or a dedicated repurchase loan. The program is valid for 12 months.お知らせ • Apr 15Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang Chinaお知らせ • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2025 Results on Apr 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Jan 16Zhejiang Nhu Company Ltd. Announces Special Dividend of the Year 2024 of A Shares, Payable on 22 January 2025Zhejiang NHU Company Ltd. announced special cash dividend/10 shares (tax included) of CNY 5.00000000 for year 2024 of A shares. Record date is 21 January 2025. Ex-date is 22 January 2025. Payment date is 22 January 2025.お知らせ • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025Zhejiang NHU Company Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025お知らせ • Dec 20Zhejiang NHU Company Ltd. Proposes Special Cash Dividend for the Third Quarter of 2024Zhejiang NHU Company Ltd. proposed special cash dividend of CNY 2.00 per 10 shares for the third quarter of 2024.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.20 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.20 in 3Q 2023). Revenue: CN¥5.94b (up 65% from 3Q 2023). Net income: CN¥1.79b (up 189% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥22.57, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.71 per share.お知らせ • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2024 Results on Oct 24, 2024Zhejiang NHU Company Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.27 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.27 in 2Q 2023). Revenue: CN¥5.35b (up 41% from 2Q 2023). Net income: CN¥1.33b (up 59% from 2Q 2023). Profit margin: 25% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Jun 29Zhejiang NHU Company Ltd. to Report First Half, 2024 Results on Aug 23, 2024Zhejiang NHU Company Ltd. announced that they will report first half, 2024 results on Aug 23, 2024お知らせ • May 25Zhejiang NHU Company Ltd. Proposes Final Cash Dividend (A Shares) for the Year 2023, Payable on 29 May 2024Zhejiang NHU Company Ltd. Proposed final cash dividend (A shares) (tax included) of CNY 4.50000000 per ten shares for the year 2023. Record date: 28 May 2024, Ex-date: 29 May 2024, Payment date: 29 May 2024. Net cash dividend/10 shares after tax: CNY 4.05000000 (CNY 4.50000000- CNY 0.45000000).Reported Earnings • Apr 24Full year 2023 earnings released: EPS: CN¥0.88 (vs CN¥1.17 in FY 2022)Full year 2023 results: EPS: CN¥0.88 (down from CN¥1.17 in FY 2022). Revenue: CN¥15.1b (down 5.1% from FY 2022). Net income: CN¥2.70b (down 25% from FY 2022). Profit margin: 18% (down from 23% in FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.お知らせ • Apr 23Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang Chinaお知らせ • Mar 30Zhejiang NHU Company Ltd. to Report Q1, 2024 Results on Apr 30, 2024Zhejiang NHU Company Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024お知らせ • Dec 29Zhejiang NHU Company Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024Zhejiang NHU Company Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.26 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.26 in 3Q 2022). Revenue: CN¥3.59b (down 2.7% from 3Q 2022). Net income: CN¥618.0m (down 23% from 3Q 2022). Profit margin: 17% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.お知らせ • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2023 Results on Oct 27, 2023Zhejiang NHU Company Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023お知らせ • Sep 21Zhejiang NHU Company Ltd. Announces Executive AppointmentsZhejiang NHU Company Ltd. at the Extraordinary General Meeting of 2023 on 19 September 2023 approved election of non-independent directors, cumulative voting system applicable: Yu Hongwei; Election of independent directors, cumulative voting system applicable: Shen Yuping, Wan Feng, Wang Yang; Election of non-employee supervisors, cumulative voting system applicable: Zhao Jia and Wang Xiaobi.Reported Earnings • Aug 30Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.33 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥3.81b (down 2.6% from 2Q 2022). Net income: CN¥840.1m (down 17% from 2Q 2022). Profit margin: 22% (down from 26% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 09Zhejiang NHU Company Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 14, 2023Zhejiang NHU Company Ltd. announced final cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2022. Record date is June 13, 2023. Ex-date is May June 14, 2023. Payment date is June 14, 2023.お知らせ • May 23Zhejiang NHU Company Ltd. Approves Cash Dividend for 2022Zhejiang NHU Company Ltd. at its Annual General Meeting of 2022 held on 19 May 2023, approved cash dividend/10 shares (tax included): CNY 5.00000000.Reported Earnings • Apr 21First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.39 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.39 in 1Q 2022). Revenue: CN¥3.61b (down 16% from 1Q 2022). Net income: CN¥643.2m (down 47% from 1Q 2022). Profit margin: 18% (down from 28% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 25Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.40 in FY 2021)Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.40 in FY 2021). Revenue: CN¥15.9b (up 7.7% from FY 2021). Net income: CN¥3.64b (down 16% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.26 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥3.69b (up 13% from 3Q 2021). Net income: CN¥797.2m (down 17% from 3Q 2021). Profit margin: 22% (down from 30% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥18.31, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.65 per share.Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.42 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.33 (down from CN¥0.42 in 2Q 2021). Revenue: CN¥3.91b (up 10% from 2Q 2021). Net income: CN¥1.01b (down 21% from 2Q 2021). Profit margin: 26% (down from 36% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.44 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.47 (up from CN¥0.44 in 1Q 2021). Revenue: CN¥4.31b (up 15% from 1Q 2021). Net income: CN¥1.20b (up 5.9% from 1Q 2021). Profit margin: 28% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥1.68 (vs CN¥1.38 in FY 2020)Full year 2021 results: EPS: CN¥1.68 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 44% from FY 2020). Net income: CN¥4.32b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.67 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 43% from FY 2020). Net income: CN¥4.31b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 5.1%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.28 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.26b (up 50% from 3Q 2020). Net income: CN¥957.6m (up 32% from 3Q 2020). Profit margin: 29% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 20Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.51 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.51b (up 31% from 2Q 2020). Net income: CN¥1.27b (down 2.8% from 2Q 2020). Profit margin: 36% (down from 49% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.42 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.74b (up 43% from 1Q 2020). Net income: CN¥1.14b (up 26% from 1Q 2020). Profit margin: 30% (down from 34% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥1.66 (vs CN¥1.01 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.3b (up 35% from FY 2019). Net income: CN¥3.56b (up 64% from FY 2019). Profit margin: 35% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 20New 90-day high: CN¥42.75The company is up 28% from its price of CN¥33.31 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.02 per share.Is New 90 Day High Low • Jan 20New 90-day high: CN¥41.05The company is up 46% from its price of CN¥28.06 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.55 per share.Valuation Update With 7 Day Price Move • Jan 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥39.29, the stock is trading at a trailing P/E ratio of 24.7x, up from the previous P/E ratio of 21.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 64%.Is New 90 Day High Low • Dec 31New 90-day high: CN¥33.68The company is up 13% from its price of CN¥29.79 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.92 per share.Is New 90 Day High Low • Dec 09New 90-day high: CN¥33.40The company is up 6.0% from its price of CN¥31.46 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.70 per share.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥3.40b, up 51% from the prior year. Total revenue was CN¥9.33b over the last 12 months, up 21% from the prior year.Analyst Estimate Surprise Post Earnings • Oct 29Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 31% at CN¥2.18b. Revenue is forecast to grow 45% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China.Is New 90 Day High Low • Oct 20New 90-day low: CN¥28.51The company is down 5.0% from its price of CN¥30.12 on 22 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.10 per share.業績と収益の成長予測XSEC:002001 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202829,60110,1089,41112,121712/31/202727,9359,2188,44411,180812/31/202627,4499,4557,0118,33293/31/202623,1066,7126,9318,885N/A12/31/202522,2516,7646,8978,797N/A9/30/202522,4707,2006,1788,139N/A6/30/202522,8667,2686,7778,177N/A3/31/202522,5506,8796,8728,188N/A12/31/202421,6105,8695,4737,073N/A9/30/202419,8864,5934,8567,071N/A6/30/202417,5433,4253,1176,022N/A3/31/202416,0032,9311,3125,209N/A12/31/202315,1172,7046745,119N/A9/30/202315,0362,710-9024,459N/A6/30/202315,1372,890-1,1494,355N/A3/31/202315,2383,060-8654,330N/A1/1/202315,9343,620-5704,361N/A9/30/202216,2133,9753324,509N/A6/30/202215,7924,1438444,791N/A3/31/202215,4354,4151,5375,176N/A1/1/202214,9174,3562,3655,838N/A9/30/202113,4554,0201,9864,935N/A6/30/202112,3513,7821,6844,285N/A3/31/202111,4803,8081,4933,949N/A12/31/202010,3143,5647703,123N/A9/30/20209,3383,398-953,053N/A6/30/20209,0743,221-1,2482,479N/A3/31/20208,4492,554-2,1222,110N/A12/31/20197,6602,165N/A2,107N/A9/30/20197,7602,244N/A2,255N/A6/30/20197,9212,173N/A2,603N/A3/31/20197,4742,096N/A3,522N/A12/31/20188,6833,079N/A3,660N/A9/30/20188,8623,341N/A3,017N/A6/30/20188,2783,177N/A2,711N/A3/31/20188,0532,966N/A1,590N/A12/31/20176,2351,704N/A1,324N/A9/30/20175,3661,258N/A1,249N/A6/30/20175,0021,273N/A1,178N/A3/31/20174,8381,279N/A1,137N/A12/31/20164,6961,203N/A1,190N/A9/30/20164,414962N/A1,202N/A6/30/20164,194732N/A1,090N/A3/31/20163,951477N/A1,042N/A12/31/20153,823402N/A972N/A9/30/20153,965380N/A758N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 002001の予測収益成長率 (年間11.8% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 002001の収益 ( 11.8% ) CN市場 ( 27.5% ) よりも低い成長が予測されています。高成長収益: 002001の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 002001の収益 ( 7.9% ) CN市場 ( 16.8% ) よりも低い成長が予測されています。高い収益成長: 002001の収益 ( 7.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 002001の 自己資本利益率 は、3年後には高くなると予測されています ( 20.1 %)成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 05:21終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zhejiang NHU Company Ltd. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Xiongwei JiaChina International Capital Corporation LimitedSophia ZhangChina Stock Investment Research Co. Ltd. (DeepValue.online)Zhe WangCitic Securities Co., Ltd.15 その他のアナリストを表示
お知らせ • Jun 30Zhejiang NHU Company Ltd. to Report First Half, 2026 Results on Aug 20, 2026Zhejiang NHU Company Ltd. announced that they will report first half, 2026 results on Aug 20, 2026
お知らせ • Jun 25Zhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for CNY 600 million worth of its shares.Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 45.5 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan and shares not used within 3 years after the completion of the repurchase will be cancelled. The program will be funded using the company's own funds. The program is valid for 12 months from board approval date.
Declared Dividend • May 23Dividend of CN¥0.80 announcedShareholders will receive a dividend of CN¥0.80. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 28% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 16Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China
お知らせ • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2026 Results on Apr 29, 2026Zhejiang NHU Company Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2025 Results on Apr 16, 2026Zhejiang NHU Company Ltd. announced that they will report fiscal year 2025 results on Apr 16, 2026
お知らせ • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2025 Results on Oct 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Sep 16Zhejiang Nhu Company Ltd. Approves Interim Dividend for 2025Zhejiang NHU Company Ltd. held its 2nd Extraordinary General Meeting of 2025 on 12 September 2025, approved interim Cash dividend/10 shares (tax included): CNY2.00000000 for 2025.
お知らせ • Aug 29Zhejiang Nhu Company Ltd. Proposes Interim Cash Dividend for 2025Zhejiang NHU Company Ltd. proposed 2025 interim dividend at its EGM to be held on 12 September 2025, a Cash dividend (tax included) of CNY 2.00000000 per ten shares.
お知らせ • Jul 02Zhejiang NHU Company Ltd. to Report First Half, 2025 Results on Aug 28, 2025Zhejiang NHU Company Ltd. announced that they will report first half, 2025 results on Aug 28, 2025
お知らせ • Apr 16+ 1 more updateZhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for $600 million worth of its shares.Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 32 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan. The program will be funded using the company's own funds or a dedicated repurchase loan. The program is valid for 12 months.
お知らせ • Apr 15Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China
お知らせ • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2025 Results on Apr 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Jan 16Zhejiang Nhu Company Ltd. Announces Special Dividend of the Year 2024 of A Shares, Payable on 22 January 2025Zhejiang NHU Company Ltd. announced special cash dividend/10 shares (tax included) of CNY 5.00000000 for year 2024 of A shares. Record date is 21 January 2025. Ex-date is 22 January 2025. Payment date is 22 January 2025.
お知らせ • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025Zhejiang NHU Company Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025
お知らせ • Dec 20Zhejiang NHU Company Ltd. Proposes Special Cash Dividend for the Third Quarter of 2024Zhejiang NHU Company Ltd. proposed special cash dividend of CNY 2.00 per 10 shares for the third quarter of 2024.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.20 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.20 in 3Q 2023). Revenue: CN¥5.94b (up 65% from 3Q 2023). Net income: CN¥1.79b (up 189% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥22.57, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.71 per share.
お知らせ • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2024 Results on Oct 24, 2024Zhejiang NHU Company Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.27 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.27 in 2Q 2023). Revenue: CN¥5.35b (up 41% from 2Q 2023). Net income: CN¥1.33b (up 59% from 2Q 2023). Profit margin: 25% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 29Zhejiang NHU Company Ltd. to Report First Half, 2024 Results on Aug 23, 2024Zhejiang NHU Company Ltd. announced that they will report first half, 2024 results on Aug 23, 2024
お知らせ • May 25Zhejiang NHU Company Ltd. Proposes Final Cash Dividend (A Shares) for the Year 2023, Payable on 29 May 2024Zhejiang NHU Company Ltd. Proposed final cash dividend (A shares) (tax included) of CNY 4.50000000 per ten shares for the year 2023. Record date: 28 May 2024, Ex-date: 29 May 2024, Payment date: 29 May 2024. Net cash dividend/10 shares after tax: CNY 4.05000000 (CNY 4.50000000- CNY 0.45000000).
Reported Earnings • Apr 24Full year 2023 earnings released: EPS: CN¥0.88 (vs CN¥1.17 in FY 2022)Full year 2023 results: EPS: CN¥0.88 (down from CN¥1.17 in FY 2022). Revenue: CN¥15.1b (down 5.1% from FY 2022). Net income: CN¥2.70b (down 25% from FY 2022). Profit margin: 18% (down from 23% in FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
お知らせ • Apr 23Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China
お知らせ • Mar 30Zhejiang NHU Company Ltd. to Report Q1, 2024 Results on Apr 30, 2024Zhejiang NHU Company Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
お知らせ • Dec 29Zhejiang NHU Company Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024Zhejiang NHU Company Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.26 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.26 in 3Q 2022). Revenue: CN¥3.59b (down 2.7% from 3Q 2022). Net income: CN¥618.0m (down 23% from 3Q 2022). Profit margin: 17% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.
お知らせ • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2023 Results on Oct 27, 2023Zhejiang NHU Company Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
お知らせ • Sep 21Zhejiang NHU Company Ltd. Announces Executive AppointmentsZhejiang NHU Company Ltd. at the Extraordinary General Meeting of 2023 on 19 September 2023 approved election of non-independent directors, cumulative voting system applicable: Yu Hongwei; Election of independent directors, cumulative voting system applicable: Shen Yuping, Wan Feng, Wang Yang; Election of non-employee supervisors, cumulative voting system applicable: Zhao Jia and Wang Xiaobi.
Reported Earnings • Aug 30Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.33 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥3.81b (down 2.6% from 2Q 2022). Net income: CN¥840.1m (down 17% from 2Q 2022). Profit margin: 22% (down from 26% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 09Zhejiang NHU Company Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 14, 2023Zhejiang NHU Company Ltd. announced final cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2022. Record date is June 13, 2023. Ex-date is May June 14, 2023. Payment date is June 14, 2023.
お知らせ • May 23Zhejiang NHU Company Ltd. Approves Cash Dividend for 2022Zhejiang NHU Company Ltd. at its Annual General Meeting of 2022 held on 19 May 2023, approved cash dividend/10 shares (tax included): CNY 5.00000000.
Reported Earnings • Apr 21First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.39 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.39 in 1Q 2022). Revenue: CN¥3.61b (down 16% from 1Q 2022). Net income: CN¥643.2m (down 47% from 1Q 2022). Profit margin: 18% (down from 28% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 25Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.40 in FY 2021)Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.40 in FY 2021). Revenue: CN¥15.9b (up 7.7% from FY 2021). Net income: CN¥3.64b (down 16% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.26 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥3.69b (up 13% from 3Q 2021). Net income: CN¥797.2m (down 17% from 3Q 2021). Profit margin: 22% (down from 30% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥18.31, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.65 per share.
Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.42 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.33 (down from CN¥0.42 in 2Q 2021). Revenue: CN¥3.91b (up 10% from 2Q 2021). Net income: CN¥1.01b (down 21% from 2Q 2021). Profit margin: 26% (down from 36% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.44 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.47 (up from CN¥0.44 in 1Q 2021). Revenue: CN¥4.31b (up 15% from 1Q 2021). Net income: CN¥1.20b (up 5.9% from 1Q 2021). Profit margin: 28% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥1.68 (vs CN¥1.38 in FY 2020)Full year 2021 results: EPS: CN¥1.68 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 44% from FY 2020). Net income: CN¥4.32b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.
Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.67 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 43% from FY 2020). Net income: CN¥4.31b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 5.1%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.28 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.26b (up 50% from 3Q 2020). Net income: CN¥957.6m (up 32% from 3Q 2020). Profit margin: 29% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 20Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.51 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.51b (up 31% from 2Q 2020). Net income: CN¥1.27b (down 2.8% from 2Q 2020). Profit margin: 36% (down from 49% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.42 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.74b (up 43% from 1Q 2020). Net income: CN¥1.14b (up 26% from 1Q 2020). Profit margin: 30% (down from 34% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥1.66 (vs CN¥1.01 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.3b (up 35% from FY 2019). Net income: CN¥3.56b (up 64% from FY 2019). Profit margin: 35% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 20New 90-day high: CN¥42.75The company is up 28% from its price of CN¥33.31 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.02 per share.
Is New 90 Day High Low • Jan 20New 90-day high: CN¥41.05The company is up 46% from its price of CN¥28.06 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.55 per share.
Valuation Update With 7 Day Price Move • Jan 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥39.29, the stock is trading at a trailing P/E ratio of 24.7x, up from the previous P/E ratio of 21.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 64%.
Is New 90 Day High Low • Dec 31New 90-day high: CN¥33.68The company is up 13% from its price of CN¥29.79 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.92 per share.
Is New 90 Day High Low • Dec 09New 90-day high: CN¥33.40The company is up 6.0% from its price of CN¥31.46 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.70 per share.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥3.40b, up 51% from the prior year. Total revenue was CN¥9.33b over the last 12 months, up 21% from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 29Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 31% at CN¥2.18b. Revenue is forecast to grow 45% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China.
Is New 90 Day High Low • Oct 20New 90-day low: CN¥28.51The company is down 5.0% from its price of CN¥30.12 on 22 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.10 per share.